moclobemide has been researched along with Panic Disorder in 13 studies
Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.
moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.
Panic Disorder: A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait.
| Excerpt | Relevance | Reference |
|---|---|---|
| "An international, multicentre, double blind parallel group study compared the tolerability and efficacy of moclobemide with the selective serotonin reuptake inhibitor (SSRI) fluoxetine for panic disorder." | 9.09 | Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. ( Behnke, K; Bouwer, C; Tiller, JW, 1999) |
| "The primary objectives of this multicenter study were to determine the efficacy and safety of moclobemide, a selective reversible inhibitor of monoamino oxidase A, as drug treatment in DSM-III-R panic disorder with and without agoraphobia." | 9.09 | The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder. ( Dahl, AA; Krüger, MB, 1999) |
| "The objective of this study was to describe preliminary experience with moclobemide in the treatment of depressive disorders in the University outpatient clinic in Malaysia." | 9.08 | Preliminary experience with moclobemide for the treatment of depressive disorders in Malaysia. ( Indran, SK, 1995) |
| " We reanalyze, with complete data methods, a clinical trial previously reported using LOCF, comparing placebo and five dosage levels of moclobemide in the treatment of outpatients with panic disorder to illustrate the superiority of methods using repeated observations." | 7.76 | Improved statistical analysis of moclobemide dose effects on panic disorder treatment. ( Klein, DF; Ross, DC; Uhlenhuth, EH, 2010) |
| " This case report deals with a patient with a long history of panic disturbances including agoraphobia, social phobia, depressive moods and alcohol abuse, whose condition remitted only after applying a supplementary treatment, using Imipramine and Moclobimide in conjunction with behavioural therapy." | 7.69 | [Treatment refractory panic disorder--success of a combined treatment with imipramine, moclobemide and behavior therapy]. ( Boerner, RJ, 1995) |
| "In the treatment of panic disorder with agoraphobia, the efficacy of pharmacological, psychological and combined treatments has been established." | 6.69 | Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia. ( Benkert, O; Graf-Morgenstern, M; Hain, C; Hautzinger, M; Loerch, B; Sandmann, J; Schlegel, S, 1999) |
| "Moclobemide is a reversible selective inhibitor of monoamine oxidase A." | 6.68 | Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder. ( Behnke, K; Bouwer, C; Tiller, JW, 1997) |
| "An international, multicentre, double blind parallel group study compared the tolerability and efficacy of moclobemide with the selective serotonin reuptake inhibitor (SSRI) fluoxetine for panic disorder." | 5.09 | Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. ( Behnke, K; Bouwer, C; Tiller, JW, 1999) |
| "The primary objectives of this multicenter study were to determine the efficacy and safety of moclobemide, a selective reversible inhibitor of monoamino oxidase A, as drug treatment in DSM-III-R panic disorder with and without agoraphobia." | 5.09 | The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder. ( Dahl, AA; Krüger, MB, 1999) |
| "The objective of this study was to describe preliminary experience with moclobemide in the treatment of depressive disorders in the University outpatient clinic in Malaysia." | 5.08 | Preliminary experience with moclobemide for the treatment of depressive disorders in Malaysia. ( Indran, SK, 1995) |
| " We reanalyze, with complete data methods, a clinical trial previously reported using LOCF, comparing placebo and five dosage levels of moclobemide in the treatment of outpatients with panic disorder to illustrate the superiority of methods using repeated observations." | 3.76 | Improved statistical analysis of moclobemide dose effects on panic disorder treatment. ( Klein, DF; Ross, DC; Uhlenhuth, EH, 2010) |
| " This case report deals with a patient with a long history of panic disturbances including agoraphobia, social phobia, depressive moods and alcohol abuse, whose condition remitted only after applying a supplementary treatment, using Imipramine and Moclobimide in conjunction with behavioural therapy." | 3.69 | [Treatment refractory panic disorder--success of a combined treatment with imipramine, moclobemide and behavior therapy]. ( Boerner, RJ, 1995) |
| "In the treatment of panic disorder with agoraphobia, the efficacy of pharmacological, psychological and combined treatments has been established." | 2.69 | Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia. ( Benkert, O; Graf-Morgenstern, M; Hain, C; Hautzinger, M; Loerch, B; Sandmann, J; Schlegel, S, 1999) |
| "Moclobemide is a reversible selective inhibitor of monoamine oxidase A." | 2.68 | Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder. ( Behnke, K; Bouwer, C; Tiller, JW, 1997) |
| "Moclobemide has shown unequivocal antidepressant activity against serious depressive illness in 4 placebo-controlled double-blind trials." | 1.29 | Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders. ( Gimbrett, R; Priest, RG; Roberts, M; Steinert, J, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (84.62) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ross, DC | 1 |
| Klein, DF | 1 |
| Uhlenhuth, EH | 2 |
| Indran, SK | 1 |
| Priest, RG | 1 |
| Gimbrett, R | 1 |
| Roberts, M | 1 |
| Steinert, J | 1 |
| Boerner, RJ | 1 |
| Joffe, RT | 1 |
| Bakish, D | 2 |
| Griebel, G | 1 |
| Perrault, G | 1 |
| Sanger, DJ | 1 |
| Tiller, JW | 2 |
| Bouwer, C | 2 |
| Behnke, K | 2 |
| Stein, MB | 1 |
| Krüger, MB | 1 |
| Dahl, AA | 1 |
| Loerch, B | 1 |
| Graf-Morgenstern, M | 1 |
| Hautzinger, M | 1 |
| Schlegel, S | 1 |
| Hain, C | 1 |
| Sandmann, J | 1 |
| Benkert, O | 1 |
| Warner, TD | 1 |
| Matuzas, W | 1 |
1 review available for moclobemide and Panic Disorder
| Article | Year |
|---|---|
Medication treatments for panic disorder and social phobia.
Topics: Antidepressive Agents, Tricyclic; Benzamides; Benzodiazepines; Citalopram; Clinical Trials as Topic; | 1998 |
7 trials available for moclobemide and Panic Disorder
| Article | Year |
|---|---|
Preliminary experience with moclobemide for the treatment of depressive disorders in Malaysia.
Topics: Adult; Antidepressive Agents; Benzamides; Depressive Disorder; Dizziness; Female; Follow-Up Studies; | 1995 |
Combined SSRI-moclobemide treatment of psychiatric illness.
Topics: 1-Naphthylamine; Adult; Benzamides; Depressive Disorder; Drug Administration Schedule; Drug Therapy, | 1994 |
Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder.
Topics: Adult; Anxiety; Benzamides; Blood Pressure; Female; Fluoxetine; Humans; Male; Moclobemide; Monoamine | 1997 |
Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group.
Topics: Adult; Benzamides; Double-Blind Method; Female; Fluoxetine; Headache; Humans; Male; Moclobemide; Mon | 1999 |
The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder.
Topics: Adult; Aged; Benzamides; Chi-Square Distribution; Chronic Disease; Clomipramine; Female; Humans; Mal | 1999 |
Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia.
Topics: Adolescent; Adult; Aged; Agoraphobia; Analysis of Variance; Antidepressive Agents; Benzamides; Cogni | 1999 |
Interactive model of therapeutic response in panic disorder: moclobemide, a case in point.
Topics: Adolescent; Adult; Analysis of Variance; Antidepressive Agents; Chi-Square Distribution; Dose-Respon | 2002 |
5 other studies available for moclobemide and Panic Disorder
| Article | Year |
|---|---|
Improved statistical analysis of moclobemide dose effects on panic disorder treatment.
Topics: Analysis of Variance; Antidepressive Agents; Clinical Trials as Topic; Female; Humans; Likelihood Fu | 2010 |
Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders.
Topics: Alzheimer Disease; Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivity; | 1995 |
[Treatment refractory panic disorder--success of a combined treatment with imipramine, moclobemide and behavior therapy].
Topics: Adult; Agoraphobia; Antidepressive Agents; Behavior Therapy; Benzamides; Combined Modality Therapy; | 1995 |
Behavioural profiles of the reversible monoamine-oxidase-A inhibitors befloxatone and moclobemide in an experimental model for screening anxiolytic and anti-panic drugs.
Topics: Animals; Anxiety; Avoidance Learning; Benzamides; Disease Models, Animal; Dose-Response Relationship | 1997 |
Reversible monoamine-A inhibitors in panic disorder.
Topics: Agoraphobia; Benzamides; Humans; Moclobemide; Monoamine Oxidase Inhibitors; Panic Disorder; Psychiat | 1992 |